Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Large granular lymphocyte (LGL) leukemia is characterized by the expansion of antigen-activated cytotoxic T lymphocytes. These leukemic cells are resistant to Fas-mediated apoptosis despite expressing high levels of Fas. We found that leukemic LGL from 19 patients displayed high levels of activated STAT3. Treatment of leukemic LGL with the JAK-selective tyrosine kinase inhibitor AG-490 induced apoptosis with a corresponding decrease in STAT-DNA binding activity. Moreover, using an antisense oligonucleotide approach to diminish STAT3 expression, we found that Fas sensitivity was restored in leukemic LGL. AG-490-induced apoptosis in leukemic LGL was independent of Bcl-xL or Bcl-2 expression. However, we found that the Bcl-2-family protein Mcl-1 was significantly reduced by AG-490 treatment. Activated STAT3 was shown to bind an SIE-related element in the murine mcl-1 promoter. Using a luciferase reporter assay, we demonstrated that v-src overexpression in NIH3T3 induced STAT3-dependent transcriptional activity from the mcl-1 promoter and increased endogenous Mcl-1 protein levels. We conclude that STAT3 activation contributed to accumulation of the leukemic LGL clones. These findings suggest that investigation should focus on novel strategies targeting STAT3 in the treatment of LGL leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other inhibition strategies include the introduction of antisense oligonucleotides, as in the case of the Isis Pharmaceuticals, Inc/AstraZeneca drug in clinical development, designed to cause degradation of STAT3 mRNA or prevent its translation via complementary base pairing, thereby reducing total STAT3 protein levels.105”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [105]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the STAT3 protein in the peripheral blood mononuclear cell extracts isolated from patients with large granular lymphocyte leukemia has been reported to bind to the murine SIE motif (9).”
The cited source says what the claim attributes to it.
In the citing paper
“IL-6 plays a significant role in inducing tumor growth as it interacts with the receptor, JAK, to induce STAT-3 activation. STAT-3 then activates oncogenes such as MCL-1 (29) and upregulates genes involved in proliferation such as Cyclin-D1 (30). These activities result in the induction of cancer cell proliferation.”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., et al. (1995) · Nature · doi:10.1038/376037a0 · Cited by 3,979 · cited 2×
“Proteolytic cleavage and activation of a cascade of caspases (death proteases) mediate the cleavage of cellular targets, resulting in programmed cell death (38, 39).”
BackgroundLymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., & Nagata, S. (1992) · Nature · doi:10.1038/356314a0 · Cited by 2,885 · cited 1×
“Animal models of lymphoproliferative disorders with autoimmune features such as lpr/lpr and gld/gld mice are characterized by insensitivity to Fasdependent cell death due to mutations in the FasR or FasL, respectively (6, 7).”
BackgroundBromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Self-citationGeneralized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand
Takahashi, T., Tanaka, M., Brannan, C. I., Jenkins, N. A., Copeland, N. G., Suda, T., & Nagata, S. (1994) · Cell · doi:10.1016/0092-8674(94)90375-1 · Cited by 1,528 · cited 1×
“Animal models of lymphoproliferative disorders with autoimmune features such as lpr/lpr and gld/gld mice are characterized by insensitivity to Fasdependent cell death due to mutations in the FasR or FasL, respectively (6, 7).”
BackgroundMCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.
Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., & Craig, R. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3516 · Cited by 961
Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931 · cited 11×
“Transfection of the indicated plasmids into NIH3T3 cells was performed using CaP04, as described previously (28). pM-v-src and pSG5-STAT3β are plasmid vectors expressing v-src and a dominant negative mutant of STAT3, respectively.”
MethodInfluentialSelf-citationInhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., et al. (1996) · Nature · doi:10.1038/379645a0 · Cited by 897 · cited 2×
“Therefore, we used a tyrphostin inhibitor (AG-490) selective for the JAKfamily tyrosine kinases to determine whether inhibition of the pathway upstream of STAT activation would affect apoptosis in LGL leukemia cells (32).”
MethodWakao, H., Gouilleux, F., & Groner, B. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06495.x · Cited by 826 · cited 2×
“The degree of binding was determined by electrophoretic analysis on a 5% native polyacrylamide gel as described previously (19, 31).”
BackgroundMethod
Cited by
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
“Blocking either of these STAT proteins in human tumour cells has been shown to downregulate MCL1 expression and induce tumour-cell apoptosi”
BackgroundSelf-citationCrosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Newell-Price, J., Bertagna, X., Grossman, A. B., & Nieman, L. K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68699-6 · Cited by 1,165
Buettner, R., Mora, L. B., & Jove, R. (2002) · PubMed · Cited by 1,185
Self-citationDe Bosscher, K., Vanden Berghe, W., & Haegeman, G. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0006 · Cited by 898
Bromberg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15617 · Cited by 770
“Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocytemacrophage colony-stimulating factor-delayed apoptosis in human neutrophils.”
BackgroundInfluentialSomatic STAT3 Mutations in Large Granular Lymphocytic Leukemia
Koskela, H. L. M., Eldfors, S., Ellonen, P., van Adrichem, A. J., Kuusanmäki, H., Andersson, E. I., Lagström, S., Clemente, M. J., Olson, T., Jalkanen, S. E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114885 · Cited by 777
Self-citationJAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis
Steelman, L. S., Pohnert, S. C., Shelton, J. G., Franklin, R. A., Bertrand, F. E., & McCubrey, J. A. (2004) · Leukemia · doi:10.1038/sj.leu.2403241 · Cited by 684
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
“MCL1 and BCL2L1 (BCLXL) are frequently amplified or overexpressed in numerous tumor types (39–42), and increased MCL1 transcription can result from amplification of the transcription factor DEK (43) or constitutive activation of STAT3 (44).”
STAT proteins: From normal control of cellular events to tumorigenesis
Calò, V., Migliavacca, M., Bazan, V., Macaluso, M., Buscemi, M., Gebbia, N., & Russo, A. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10364 · Cited by 610
“One of these is the use of antisense oligomers against STAT3 in order to inhibit cell growth in head and neck squamous carcinoma cell lines and in prostate cancer cells (Grandis et al., 1998; Epling-Burnette et al., 2001).”
BackgroundGritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1752 · Cited by 563
Self-citationSTAT3 Target Genes Relevant to Human Cancers
Carpenter, R., & Lo, H.-W. (2014) · Cancers · doi:10.3390/cancers6020897 · Cited by 511
“EMSA experiments later showed that STAT3 can directly bind these STAT3 elements within the MCL1 promoter and drive gene activation in LGL leukemia cells [37].”
BackgroundInfluentialSong, H., Wang, R., Wang, S., & Lin, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409894102 · Cited by 504
STAT3 as a target for inducing apoptosis in solid and hematological tumors
Al Zaid Siddiquee, K., & Turkson, J. (2008) · Cell Research · doi:10.1038/cr.2008.18 · Cited by 487
Self-citationTurkson, J., Ryan, D., Kim, J. S., Zhang, Y., Chen, Z., Haura, E., Laudano, A., Sebti, S., Hamilton, A. D., & Jove, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107527200 · Cited by 448
Self-citationAoki, Y., Feldman, G. M., & Tosato, G. (2003) · Blood · doi:10.1182/blood-2002-07-2130 · Cited by 438
“Tyrphostin AG490 is described as a JAK2 inhibitor leading to suppression of constitutively activated STAT3 molecules in acute leukemias and multiple myelomas.(32,33) We looked for this effect of AG490 in PEL.”
BackgroundInfluentialHaura, E. B., Turkson, J., & Jove, R. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0195 · Cited by 430
“In a myeloma tumor model, interleukin (IL)-6-dependent Stat3 signaling upregulates the promoter of the apoptosis regulator Bcl-X, which contributes to cell survival, while in large granular T-lymphocyte cells, cytokine-dependent Stat3 signaling is necessary for transcriptional upregulation of Mcl-1, a member of the Bc…”
BackgroundSelf-citationRoles of activated Src and Stat3 signaling in melanoma tumor cell growth
Niu, G., Bowman, T., Huang, M., Shivers, S., Reintgen, D., Daud, A., Chang, A., Kraker, A., Jove, R., & Yu, H. (2002) · Oncogene · doi:10.1038/sj.onc.1205859 · Cited by 432
“…is required for proliferation and survival, up-regulation of pro-growth genes, including Bcl-xL, Mcl-1, cyclin D1 and c-Myc, has been reported (Bowman et al., 2001; Bromberg et al., 1999; Catlett-Falcone et al., 1999b; Epling-Burnette et al., 2001; Grandis et al., 2000; Sinibaldi et al., 2000).”
BackgroundSelf-citationJerez, A., Clemente, M. J., Makishima, H., Koskela, H., LeBlanc, F., Peng Ng, K., Olson, T., Przychodzen, B., Afable, M., Gomez-Segui, I., et al. (2012) · Blood · doi:10.1182/blood-2012-06-435297 · Cited by 424
Self-citationCorvinus, F. M., Orth, C., Moriggl, R., Tsareva, S. A., Wagner, S., Pfitzner, E. B., Baus, D., Kaufman, R., Huber, L. A., Zatloukal, K., et al. (2005) · Neoplasia · doi:10.1593/neo.04571 · Cited by 427
“Cell transformation by aberrant STAT3 activity probably involves upregulation of genes promoting cell cycle progression (cyclin D1 and c-myc) and/or preventing apoptosis (bcl-xL, mcl-1, and survivin) [15–18].”
BackgroundActivation of Stat3 in Human Melanoma Promotes Brain Metastasis
Xie, T.-X., Huang, F.-J., Aldape, K. D., Kang, S.-H., Liu, M., Gershenwald, J. E., Xie, K., Sawaya, R., & Huang, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2674 · Cited by 393
Gleave, M. E., & Monia, B. P. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1631 · Cited by 384
“Reduction in STAT3 expression promotes tumour-cell death and increases sensitivity to chemotherapeutic agents in a range of tumour types in vitro and human xenograft models in vivo , including multiple myeloma, melanoma, lymphoma and prostate tumou”
BackgroundTargeting multiple signal transduction pathways through inhibition of Hsp90
Zhang, H., & Burrows, F. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0549-9 · Cited by 377
“Studies have shown that suppression of STAT3 and STAT5 with small molecule inhibitors causes retardation of tumor growth and induction of apoptosis [ 60 ].”
BackgroundIwamaru, A., Szymanski, S., Iwado, E., Aoki, H., Yokoyama, T., Fokt, I., Hess, K., Conrad, C., Madden, T., Sawaya, R., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210031 · Cited by 370
“The expression of Mcl-1, Bcl-XL and c-Myc in both cell types decreased markedly 24–72 h after treatment with WP1066 in U87-MG and U373-MG cells (Figure 3c).”
BackgroundInfluentialRahaman, S. O., Harbor, P. C., Chernova, O., Barnett, G. H., Vogelbaum, M. A., & Haque, S. J. (2002) · Oncogene · doi:10.1038/sj.onc.1206047 · Cited by 377
“…of apoptosis in a number of cancers, including multiple myeloma, head and neck squamous cell carcinoma, breast carcinoma, leukemia and lymphomas (Catlett-Falcone et al., 1999; Bowman et al., 2000; Grandis et al., 2000; Schuringa et al., 2000; Badache et al., 2001; Epling-Burnette et al., 2001).”
BackgroundMethodInfluentialNetwork model of survival signaling in large granular lymphocyte leukemia
Zhang, R., Shah, M. V., Yang, J., Nyland, S. B., Liu, X., Yun, J. K., Albert, R., & Loughran, T. P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806447105 · Cited by 375
“determined, and Western blot assay was performed as described (3).”
BackgroundMethodSelf-citationStructure, function, and regulation of STAT proteins
Lim, C. P., & Cao, X. (2006) · Molecular BioSystems · doi:10.1039/b606246f · Cited by 354
Song, L., Turkson, J., Karras, J. G., Jove, R., & Haura, E. B. (2003) · Oncogene · doi:10.1038/sj.onc.1206479 · Cited by 362
“…tumor model, IL-6-dependent STAT3 signaling upregulates the Bcl-x promoter and contributes to cell survival, while in large granular T cells, cytokine-dependent Stat3 signaling was necessary for transcriptional upregulation of Mcl-1 (Catlett-Falcone et al., 1999; Epling-Burnette et al., 2001a, b).”
BackgroundSelf-citationChan, K. S., Sano, S., Kiguchi, K., Anders, J., Komazawa, N., Takeda, J., & DiGiovanni, J. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421032 · Cited by 356
“It is known that several antiapoptotic molecules such as Bcl-xL (46), Bcl-2 (47), and Mcl-1 (48) are downstream targets for Stat3.”
BackgroundKartikasari, A. E. R., Huertas, C. S., Mitchell, A., & Plebanski, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.692142 · Cited by 343
“STAT-3 then activates oncogenes such as MCL-1 (29) and upregulates genes involved in proliferation such as Cyclin-D1 (30).”
BackgroundSignal transducer and activator of transcription proteins in leukemias
Benekli, M., Baer, M. R., Baumann, H., & Wetzler, M. (2003) · Blood · doi:10.1182/blood-2002-04-1204 · Cited by 325
LGL leukemia: from pathogenesis to treatment
Lamy, T., Moignet, A., & Loughran, T. P. (2017) · Blood · doi:10.1182/blood-2016-08-692590 · Cited by 302
“Constitutive activation of Stat3 in all LGL leukemia patients was first discovered in 2001.(40) In 2012, common somatic gain-of-function Stat3 mutations were demonstrated in 28% to 75% of T-LGL leukemia and 30% to 48% of NK-LGL lymphocytosis(6,41-43) (Figure 2D).”
BackgroundSelf-citationBoolean network simulations for life scientists
Albert, I., Thakar, J., Li, S., Zhang, R., & Albert, R. (2008) · Source Code for Biology and Medicine · doi:10.1186/1751-0473-3-16 · Cited by 301
Ding, B. B., Yu, J. J., Yu, R. Y.-L., Mendez, L. M., Shaknovich, R., Zhang, Y., Cattoretti, G., & Ye, B. H. (2008) · Blood · doi:10.1182/blood-2007-04-087734 · Cited by 298
Highlighted STAT3 as a potential drug target for cancer therapy
Lee, H., Jeong, A. J., & Ye, S.-K. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.7.152 · Cited by 295
Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia
Rajala, H. L. M., Eldfors, S., Kuusanmäki, H., van Adrichem, A. J., Olson, T., Lagström, S., Andersson, E. I., Jerez, A., Clemente, M. J., Yan, Y., et al. (2013) · Blood · doi:10.1182/blood-2012-12-474577 · Cited by 294
“Furthermore, in a previous study, which first described activated STAT3 in LGL leukemia, 2 of 12 patients also expressed concurrently activated STAT5.(31) Our microarray data suggest that gene expression patterns in LGL leukemia patients with different mutation status resemble each other.”
InfluentialSelf-citationBhattacharya, S., Ray, R. M., & Johnson, L. R. (2005) · Biochemical Journal · doi:10.1042/bj20050465 · Cited by 291
Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells
Nam, S., Buettner, R., Turkson, J., Kim, D., Cheng, J. Q., Muehlbeyer, S., Hippe, F., Vatter, S., Merz, K.-H., Eisenbrand, G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409467102 · Cited by 294
Self-citationSTAT proteins as novel targets for cancer drug discovery
Turkson, J. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.5.409 · Cited by 295
“Additionally, evidence has implicated a role for IL-6 in persistent Stat3 activation in cervical carcinoma cells, which is associated with Mcl-1 expression [117].”
BackgroundInfluentialSelf-citationLamy, T., & Loughran, T. P. (2011) · Blood · doi:10.1182/blood-2010-07-296962 · Cited by 290
“62 4-12 55 21 34 NR 21 (12-60) 12 relapses/18 under therapy 12 (2010)”
Self-citationKotha, A., Sekharam, M., Cilenti, L., Siddiquee, K., Khaled, A., Zervos, A. S., Carter, B., Turkson, J., & Jove, R. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0268 · Cited by 283
Self-citationTranscription Factor STAT3 as a Novel Molecular Target for Cancer Prevention
Xiong, A., Yang, Z., Shen, Y., Zhou, J., & Shen, Q. (2014) · Cancers · doi:10.3390/cancers6020926 · Cited by 283
“STAT3 positively regulates cell survival by inducing Bcl-2 and Bcl-XL to repress apoptosis [27], and inversely, STAT3 degradation and inhibition cause increased apoptosis [28,29].”
BackgroundSubramaniam, A., Shanmugam, M. K., Perumal, E., Li, F., Nachiyappan, A., Dai, X., Swamy, S. N., Ahn, K. S., Kumar, A. P., Tan, B. K. H., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.10.002 · Cited by 278
Targeting Stat3 in cancer therapy
Jing, N., & Tweardy, D. J. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200507000-00002 · Cited by 278
Jazirehi, A. R., & Bonavida, B. (2005) · Oncogene · doi:10.1038/sj.onc.1208349 · Cited by 275
“…STAT3 to activate antiapoptosis and proliferation-associated proteins such as Bcl-xL, Bcl2, Mcl-1, c-myc, Cyclin D1, and p21WAF 1 is established in various model systems (Bellido et al., 1998; CatlettFalcone et al., 1999; Kiuchi et al., 1999; Sinibaldi et al., 2000; Epling-Burnette et al., 2001).”
BackgroundInhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells
Burke, W. M., Jin, X., Lin, H.-J., Huang, M., Liu, R., Reynolds, R. K., & Lin, J. (2001) · Oncogene · doi:10.1038/sj.onc.1204990 · Cited by 269
“Moreover, blocking Stat3 signaling may also induce apoptosis independent of down regulation of Bcl-xL (Epling-Burnette et al., 2001; Niu et al., 2001).”
BackgroundCraig, R. (2002) · Leukemia · doi:10.1038/sj.leu.2402416 · Cited by 266
Malamut, G., El Machhour, R., Montcuquet, N., Martin-Lannerée, S., Dusanter-Fourt, I., Verkarre, V., Mention, J.-J., Rahmi, G., Kiyono, H., Butz, E. A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41344 · Cited by 256
Turkson, J., Kim, J. S., Zhang, S., Yuan, J., Huang, M., Glenn, M., Haura, E., Sebti, S., Hamilton, A. D., & Jove, R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.261.3.3 · Cited by 255
Self-citationBCL2 Family of Apoptosis-Related Genes: Functions and Clinical Implications in Cancer
Thomadaki, H., & Scorilas, A. (2006) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360500295626 · Cited by 245
“[91] Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R, Loughran TP Jr.”
Huang, S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2313 · Cited by 249
Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer
Mishra, A., Sullivan, L., & Caligiuri, M. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3603 · Cited by 244
Alas, S., & Bonavida, B. (2003) · PubMed · Cited by 264
Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies.
Greenstein, S., Ghias, K. K., Krett, N. L., & Rosen, S. T. (2002) · PubMed · Cited by 279
Pathak, A. K., Bhutani, M., Nair, A. S., Ahn, K. S., Chakraborty, A., Kadara, H., Guha, S., Sethi, G., & Aggarwal, B. B. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0348 · Cited by 235
“We also determined the effect of ursolic acid on Mcl-1, an antiapoptotic protein that is highly expressed in hematopoietic cells (38, 39).”
BackgroundIsomoto, H., Kobayashi, S., Werneburg, N. W., Bronk, S. F., Guicciardi, M. E., Frank, D. A., & Gores, G. J. (2005) · Hepatology · doi:10.1002/hep.20966 · Cited by 227
Haura, E. B., Zheng, Z., Song, L., Cantor, A., & Bepler, G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0827 · Cited by 223
STAT3 as a therapeutic target in head and neck cancer
Leeman, R. J., Lui, V. W. Y., & Grandis, J. R. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.3.231 · Cited by 223
Series Introduction: JAK-STAT signaling in human disease
Schindler, C. W. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15644 · Cited by 218
STAT3 in Cancer—Friend or Foe?
Zhang, H.-F., & Lai, R. (2014) · Cancers · doi:10.3390/cancers6031408 · Cited by 219
“In other studies, it has been demonstrated that STAT3β can abolish the transcriptional activation of several STAT3 downstream targets including Cyclin D1, Bcl-xL and Mcl-1, leading to inhibition of tumor growth and promotion of apoptosis [174–176].”
BackgroundHow melanoma cells evade trail-induced apoptosis
Hersey, P., & Zhang, X. D. (2001) · Nature Reviews Cancer · doi:10.1038/35101078 · Cited by 212
“cgi?Q=pik3*%20not%20hypothetical&ORG=Hs">phosphatidylinositol 3-kinase pathway”
Constitutive Activation of JAK3/STAT3 in Colon Carcinoma Tumors and Cell Lines
Lin, Q., Lai, R., Chirieac, L. R., Li, C., Thomazy, V. A., Grammatikakis, I., Rassidakis, G. Z., Zhang, W., Fujio, Y., Kunisada, K., et al. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61187-x · Cited by 207
Fitzgerald, J. S., Poehlmann, T. G., Schleussner, E., & Markert, U. R. (2008) · Human Reproduction Update · doi:10.1093/humupd/dmn010 · Cited by 205
Regulation of apoptosis by insulin-like growth factor (IGF)-I
KOOIJMAN, R. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.02.002 · Cited by 203
“[63] Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M,”
ResultAngelis, P. M. D., Kravik, K., Tunheim, S. H., Haug, T., & Reichelt, W. H. (2004) · Molecular Cancer · doi:10.1186/1476-4598-3-11 · Cited by 210
Li, F., Fernandez, P. P., Rajendran, P., Hui, K. M., & Sethi, G. (2010) · Cancer Letters · doi:10.1016/j.canlet.2009.12.003 · Cited by 201
Turkson, J., Zhang, S., Palmer, J., Kay, H., Stanko, J., Mora, L. B., Sebti, S., Yu, H., & Jove, R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1533.3.12 · Cited by 188
“Stat3 signaling is critical for the enhanced survival of malignant cells (15, 19, 20, 51, 53, 54).”
BackgroundSelf-citationSaadatpour, A., Wang, R.-S., Liao, A., Liu, X., Loughran, T. P., Albert, I., & Albert, R. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002267 · Cited by 185
“Boolean rules governing the state of the T-LGL signaling network depicted in Figure 1.”
BackgroundInfluentialSelf-citationDisruption of STAT3 by Niclosamide Reverses Radioresistance of Human Lung Cancer
You, S., Li, R., Park, D., Xie, M., Sica, G. L., Cao, Y., Xiao, Z.-Q., & Deng, X. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0608 · Cited by 182
“It has been reported that STAT3 also functions as a Mcl-1 transcriptional factor that can positively regulate Mcl-1 expression (29, 31).”
BackgroundFantin, V. R., Loboda, A., Paweletz, C. P., Hendrickson, R. C., Pierce, J. W., Roth, J. A., Li, L., Gooden, F., Korenchuk, S., Hou, X. S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6091 · Cited by 170
Zeng, H., Qu, J., Jin, N., Xu, J., Lin, C., Chen, Y., Yang, X., He, X., Tang, S., Lan, X., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.001 · Cited by 165
Li, F., Rajendran, P., & Sethi, G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00874.x · Cited by 176
Amin, H. M., McDonnell, T. J., Ma, Y., Lin, Q., Fujio, Y., Kunisada, K., Leventaki, V., Das, P., Rassidakis, G. Z., Cutler, C., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207703 · Cited by 173
Mishra, A., Liu, S., Sams, G. H., Curphey, D. P., Santhanam, R., Rush, L. J., Schaefer, D., Falkenberg, L. G., Sullivan, L., Jaroncyk, L., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.009 · Cited by 169
“The latter has been shown to induce anti-apoptotic Mcl-1 expression in patients with LGL leukemia (Epling-Burnette et al., 2001), and a recent study has uncovered activating STAT3 mutations in a subset of patients with chronic LGL leukemia (Johnston et al.”
BackgroundEmerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment
Correia, C., Lee, S.-H., Meng, X. W., Vincelette, N. D., Knorr, K. L. B., Ding, H., Nowakowski, G. S., Dai, H., & Kaufmann, S. H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.03.012 · Cited by 166
Stat3 activation in human endometrial and cervical cancers
Chen, C.-L., Hsieh, F.-C., Lieblein, J. C., Brown, J., Chan, C., Wallace, J. A., Cheng, G., Hall, B. M., & Lin, J. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603597 · Cited by 169
“597 British Journal of Cancer (2007) 96(4), 591 – 599& 2007 Cancer Research UK T ra n sl a ti o n a l T h e ra p e u ti c s (Grandis et al, 2000; Epling-Burnette et al, 2001; Calvin et al, 2003; Chiarle et al, 2005), siRNA (Konnikova et al, 2003; Lee et al, 2004), small molecules (Song et al, 2005;…”
McCarty, M. F. (2004) · Integrative Cancer Therapies · doi:10.1177/1534735404270757 · Cited by 169
Klampfer, L. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906776056491 · Cited by 171
Leu, C.-M., Wong, F.-H., Chang, C., Huang, S.-F., & Hu, C.-P. (2003) · Oncogene · doi:10.1038/sj.onc.1207084 · Cited by 168
“It has been reported that the activated STAT3 could bind to an SIE-like binding site in the mouse mcl-1 promoter and increase Mcl-1 expression in v-src-transformed NIH3T3 cells (Epling-Burnette et al., 2001).”
BackgroundInhibition of STAT3 Signaling Blocks the Anti-apoptotic Activity of IL-6 in Human Liver Cancer Cells
Liu, Y., Li, P.-K., Li, C., & Lin, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.142752 · Cited by 165
JAK/STAT signaling in hepatocellular carcinoma
Tang, J. J. H., Thng, D. K. H., Lim, J. J., & Toh, T. B. (2020) · Hepatic Oncology · doi:10.2217/hep-2020-0001 · Cited by 174
STAT3 and its targeting inhibitors in osteosarcoma
Liu, Y., Liao, S., Bennett, S., Tang, H., Song, D., Wood, D., Zhan, X., & Xu, J. (2021) · Cell Proliferation · doi:10.1111/cpr.12974 · Cited by 158
Jiang, J. X., Mikami, K., Venugopal, S., Li, Y., & Török, N. J. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.024 · Cited by 158
“STAT3 phosphorylation is strongly linked to cell survival due to the induction of Bcl-xL [13] and myeloid cell leukemia-1 protein (Mcl-1) [14].”
BackgroundSelf-citationA major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells
Jourdan, M., Veyrune, J., Vos, J. D., Redal, N., Couderc, G., & Klein, B. (2003) · Oncogene · doi:10.1038/sj.onc.1206423 · Cited by 170
“Mcl-1 is able to form heterodimers with several pro-apoptotic proteins such as Bax, Bak, Bok, Bod, Bik and the unphosphorylated form of Bad (Hsu et al., 1997; Hsu et al., 1998; Bae et al., 2001; Epling-Burnette et al., 2001a; Epling-Burnette et al., 2001b).”
BackgroundAzare, J., Leslie, K., Al-Ahmadie, H., Gerald, W., Weinreb, P. H., Violette, S. M., & Bromberg, J. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02404-06 · Cited by 153
“Many of these proteins have known roles in EMT, migration, and tumorigenesis (3, 17 , 22, 32, 37, 38, 49, 54).”
BackgroundTurkson, J., Zhang, S., Mora, L. B., Burns, A., Sebti, S., & Jove, R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502694200 · Cited by 151
Self-citationB7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation
Liu, H., Tekle, C., Chen, Y.-W., Kristian, A., Zhao, Y., Zhou, M., Liu, Z., Ding, Y., Wang, B., Mælandsmo, G. M., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0072 · Cited by 158
Brocke-Heidrich, K., Kretzschmar, A. K., Pfeifer, G., Henze, C., Löffler, D., Koczan, D., Thiesen, H.-J., Burger, R., Gramatzki, M., & Horn, F. (2004) · Blood · doi:10.1182/blood-2003-04-1048 · Cited by 150
Rajendran, P., Li, F., Shanmugam, M. K., Vali, S., Abbasi, T., Kapoor, S., Ahn, K. S., Kumar, A. P., & Sethi, G. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22954 · Cited by 148
“Mcl-1 is highly expressed in tumor cells (Epling-Burnette et al., 2001), andNiu et al. (2002) had reported that inhibition of STAT3 by a Src inhibitor results in down-regulation of expression of the Mcl-1 gene in melanoma cells.”
BackgroundJak family of kinases in cancer
Verma, A., Kambhampati, S., Parmar, S., & Platanias, L. C. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023805715476 · Cited by 161
“After treatment with the AG490 inhibitor, the Stat3 DNA binding activity was decreased, and this was accompanied by restoration of sensitivity to Fas-induced apoptosis [97], pointing to a critical role for Jak kinases in the activation of Stat3 and the pathogenesis of this leukemia.”
BackgroundInfluentialYang, Y., Chang, Y., Huang, P., Chiou, G., Tseng, L., Chiou, S., Chen, M., Chen, M., Shih, Y., Chang, C., et al. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22806 · Cited by 139
“…(STAT), a transcription factor for cytokine signaling, is constitutively activated in numerous cancer types, including prostate cancer, breast cancer, leukemia, multiple myeloma, nasopharyngeal carcinoma, and brain tumors (Bowman et al., 2000; Bromberg, 2001, 2002; Epling-Burnette et al., 2001).”
BackgroundT-Cell Large Granular Lymphocyte Leukemia and Related Disorders
Rose, M. G., & Berliner, N. (2004) · The Oncologist · doi:10.1634/theoncologist.9-3-247 · Cited by 147
Subramaniam, A., Shanmugam, M. K., Ong, T. H., Li, F., Perumal, E., Chen, L., Vali, S., Abbasi, T., Kapoor, S., Ahn, K. S., et al. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12302 · Cited by 153
“Moreover, anti-apoptotic protein Mcl-1 is highly expressed in tumour cells (Epling-Burnette et al., 2001), and the inhibition of STAT3 by a Src inhibitor can lead to downregulation of expression of Mcl-1 gene (Niu et al., 2002).”
BackgroundRheumatoid Arthritis Synoviocyte Survival Is Dependent on Stat3
Krause, A., Scaletta, N., Ji, J.-D., & Ivashkiv, L. B. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.11.6610 · Cited by 143
Garg, M., Shanmugam, M. K., Bhardwaj, V., Goel, A., Gupta, R., Sharma, A., Baligar, P., Kumar, A. P., Goh, B. C., Wang, L., et al. (2021) · Medicinal Research Reviews · doi:10.1002/med.21761 · Cited by 139
“Activated STAT3 has been reported to increase the expression of Bcl‐2, Bcl‐XL, and Mcl1 proteins to escape the apoptosis of tumor cells.(92,93) STAT3 can induce the expression of survivin for the survival and proliferation of gastric cancer cells.”
BackgroundMicroenvironmental Interactions and Survival of CLL B-cells
Pedersen, I. M., & Reed, J. C. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190412331272703 · Cited by 157
ICAM-1 induction by TNFα and IL-6 is mediated by distinct pathways via Rac in endothelial cells
Wung, B., Ni, C., & Wang, D. L. (2005) · Journal of Biomedical Science · doi:10.1007/s11373-004-8170-z · Cited by 155
“Yang-Yen of the Institute of Molecular Biology, Academia Sinica, Taiwan [ 49 ].”
BackgroundTargeting Signal Transducer and Activator of Transcription Signaling Pathway in Leukemias
Benekli, M., Baumann, H., & Wetzler, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3264 · Cited by 140
“Inhibition of upstream tyrosine kinases, such as Janus family tyrosine kinase (JAK), breakpoint cluster region-abelson tyrosine kinase, FMS-related tyrosine kinase 3, and sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian), with resultant downregulation of STATs has proven to be the most effective STAT-targeti…”
BackgroundSerine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival
Liu, H., Ma, Y., Cole, S. M., Zander, C., Chen, K.-H., Karras, J., & Pope, R. M. (2003) · Blood · doi:10.1182/blood-2002-11-3396 · Cited by 136
Self-citationSTATs: An Old Story, Yet Mesmerizing.
Abroun, S., Saki, N., Ahmadvand, M., Asghari, F., Salari, F., & Rahim, F. (2015) · PubMed · doi:10.22074/cellj.2015.1 · Cited by 68
“Studies have shown that numerous genes which encode for BCL-XL, MCL-1, cyclins D1/D2, and c-MYC proteins are downstream targets of STAT3 (7, 17, 79, 80).”
Background
Metadata
- Authors
- Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., Jove, R., & Loughran, T. P.
- Affiliations
- University of South Florida (US)
- National Taiwan University (TW)
- Ionis Pharmaceuticals (United States) (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2001-02-01
- Volume
- 107
- Issue
- 3
- Pages
- 351-362
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC199188
- OpenAlex
- W2041204531
- Cited by
- 633
- References
- 60
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 14 · 2023: 20 · 2022: 25 · 2021: 26 · 2020: 31 · 2019: 22 · 2018: 14 · 2017: 27 · 2016: 15 · 2015: 27 · 2014: 46 · 2013: 31 · 2012: 35
- FWCI
- 12.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Moffitt Cancer Center
- National Institutes of Health (5r21ca078724-02)
- National Cancer Institute (R01CA055652, CA-55652, CA78724)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- large granular lymphocyte leukemia, STAT3 signaling, apoptosis, Mcl-1, Fas resistance, AG490, antisense oligonucleotides, Bcl-2 family proteins, v-Src
- MeSH terms
- Cell Line, DNA-Binding Proteins, Enzyme Inhibitors, Gene Expression Regulation, Humans, Leukemia, Neoplasm Proteins, Phosphorylation, Tumor Cells, Cultured, Blotting, Western, Signal Transduction, Trans-Activators, Oncogene Protein pp60(v-src), Apoptosis, CD8-Positive T-Lymphocytes, Proto-Oncogene Proteins c-bcl-2, Dimerization, Tyrphostins, STAT3 Transcription Factor, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.